منابع مشابه
Fulvestrant for advanced male breast cancer patients: a case series.
Male breast cancer is rare and treatment recommendations are mainly extrapolated from the results of trials on women. Most breast cancers in men are estrogen receptor (ER)/ progesterone receptor (PgR) positive; as a consequence, tamoxifen remains the standard adjuvant treatment and is also the mainstay first-line treatment of advanced disease, with reported response rates varying from 25% to 80...
متن کاملFulvestrant in postmenopausal women with advanced breast cancer.
PURPOSE Patients with hormone-sensitive breast cancer who have responded to tamoxifen (TAM) may receive additional benefit from a second endocrine agent after progression or relapse after TAM therapy. Fulvestrant (FVT; Faslodex; i.m. injection, ICI 182,780; AstraZeneca Pharmaceuticals, Wilmington, DE) was developed as a selective antagonist of estrogen. In postmenopausal women, FVT is reported ...
متن کاملActivity of fulvestrant in HER2-overexpressing advanced breast cancer.
BACKGROUND Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only approximately 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are...
متن کاملFulvestrant and male breast cancer: a case series.
women with HER2 positive MBC. Proc Am Soc Clin Oncol 2003; 22: (Abstr 294). 3. Fyfe GA, Mass R, Murphy M et al. Survival benefit of trastuzumab (Herceptin) and chemotherapy in older (age >60) patients. Proc Am Soc Clin Oncol 2001; 20: (Abstr 189). 4. Serrano C, Cortés J, De Mattos-Arruda L et al. Trastuzumab related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Onco...
متن کاملA Review of Fulvestrant in Breast Cancer
Fulvestrant is a selective estrogen receptor degrader that binds, blocks and degrades the estrogen receptor (ER), leading to complete inhibition of estrogen signaling through the ER. This review article further explains the mechanism of action of the drug and goes on to review the trials carried out to optimize its dosing. Multiple trials have been undertaken to compare fulvestrant with other e...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2009
ISSN: 0923-7534
DOI: 10.1093/annonc/mdp413